Skip to main content
Contact Us
search

Karl M. Kilgore

Author Biography

karl.kilgore@inovalon.com
Connect on LinkedIn

Karl M. Kilgore, PhD

Director, Research Science and Advanced Analytics

Karl has over 25 years of experience designing and developing health economics & outcomes studies, descriptive & analytic epidemiology studies, outcomes-based marketing programs and disease registries.

Karls professional interests include Social Determinants of Health, how social, behavioral and genetic factors interact to impact the health of individuals and populations, risk adjustment methodologies for health performance measurement and reimbursement, and real-world outcomes of novel therapies, particularly in Oncology.

Previously, he was Senior Research Scientist, Health Economics and Advanced for Avalere Health, an Inovalon Company. Prior to joining Avalere, he was Vice President of Research and Outcomes for Cetus Group, a contract research organization serving the pharmaceutical and medical device industries.

He received his PhD in Psychology from the University of Chicago with concentration in Epidemiology, Statistical Analysis, Research Methods and Psychometrics.

Authored Content

Filter

May 21, 2023
Presentation

Development of a Social Determinants of Health Insights Dashboard to Support Organizations in Advancing Health Equity

Teigland C, Kilgore K
Accepted for presentation at Pharmaceutical Management Science Association (PMSA) 2023 Annual Conference. Findings available upon request. Contact us for more information.
Read More
December 13, 2022
Presentation

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Chihara D, Liao L, Tkacz J, Lewing B, Franco A, Kilgore K, Nastoupil L, Chen L
The aim of the study was to examine the outcomes and economic impact among older patients with DLBCL receiving CAR T-cell therapy in a real-world setting in the United States.
Read More
December 10, 2022
Presentation

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Chihara D, Liao L, Chen L,  Tkacz JP, Franco A, Lewing B, Kilgore K,   Nastoupil L 
Accepted for presentation at American Society of Hematology (ASH) Annual Meeting 2022. Findings available upon request. Contact us for more information.
Read More
April 6, 2022
Presentation

Impact of Social Determinants of Health (SDOH) and Specialist Care on Healthcare Resource Utilization (HRU) and Costs in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Kilgore K, Pareja K, Teigland C, Mohammadi I, Frank L, Agatep B, Nunna S
Accepted for presentation at National Kidney Foundation Spring Clinical Meeting 2022. Findings available upon request. Contact us for more information.
Read More
January 20, 2022
Presentation

Impact of Race/Ethnicity and Socioeconomic Status on Emergency Department Visits in Patients with Hepatocellular Carcinoma

Lin D, Tan A, Kilgore KM, Teigland CT, Hernandez S, Slay DL, Schroeder AL, Kim S
Despite advances in diagnosis and treatment of hepatocellular carcinoma (HCC), disparities in care utilization and health outcomes persist. Few studies have evaluated the impact of race/ethnicity and socioeconomic status (SES) on incidence of emergency department (ED) visits, which may reflect access to and quality of cancer care. This study investigated this relationship among patients (pts) with HCC.
Read More
November 2, 2021
Presentation

Social Determinants of Health (SDOH) and Healthcare Resource Utilization (HRU) in Autosomal Dominant Polycystic Kidney Disease (ADPKD) by Chronic Kidney Disease (CKD) Stage

Kilgore KM, Mohammadi I, Japes H, Frank LL, Aijaz TR, Teigland C, Pareja K
Accepted for presentation at ASN Kidney Week 2021. Findings available upon request. Contact us for more information.
Read More
October 14, 2021
Peer-Reviewed Article

Burden of illness and outcomes in 2nd line large B-cell lymphoma treatment: Real-world analysis of Medicare beneficiaries

Kilgore KM, Mohammadi I, Wong A, Snider J, Cheng P, Schroeder A, Patel A
To characterize elderly large B-cell lymphoma patients who progress to second-line treatment to identify potential unmet treatment needs.
Read More
February 8, 2021
Presentation

Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants

Shah GL, Mohammadi I, Purdum AG, Wong AC, Schroeder A, Kilgore KM, Shah GL
Accepted for presentation at 2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Findings available upon request. Contact us for more information.
Read More